Previous studies have reported that down-regulation of CDKN1A is not only related to the uncontrolled proliferation of cancer cells but also responsible for the resistance of some cell cycle-specific drugs such as CDK4/6 inhibitors and paclitaxel [28–30]. Here, CDKN1A is linked to cancer.